On Tuesday, Merck & Co Inc (NYSE: MRK) opened lower -1.98% from the last session, before settling in for the closing price of $100.26. Price fluctuations for MRK have ranged from $73.31 to $105.84 over the past 52 weeks.
During the last 5-year period, the sales growth of Healthcare Sector giant was 12.04%. Company’s average yearly earnings per share was noted 17.26% at the time writing. With a float of $2.48 billion, this company’s outstanding shares have now reached $2.49 billion.
Merck & Co Inc (MRK) Insider Activity
A key investor’s attitude towards the stock of the Drug Manufacturers – General industry is another important factor to consider. The insider ownership of Merck & Co Inc is 0.10%, while institutional ownership is 79.83%. The most recent insider transaction that took place on Nov 10 ’25, was worth 616,395. In this transaction Chief Comm. & Public Afrs Ofcr of this company sold 7,085 shares at a rate of $87.00, taking the stock ownership to the 0 shares. Before that another transaction happened on Nov 10 ’25, when Company’s Officer proposed sale 7,085 for $87.00, making the entire transaction worth $616,395.
Merck & Co Inc (MRK) Earnings and Forecasts
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted 1.72 earnings per share (EPS) for the quarter, besting the agreed prediction (set at 1.67) by 0.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.77 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 17.26% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 9.99% during the next five years compared to 12.04% growth over the previous five years of trading.
Merck & Co Inc (NYSE: MRK) Trading Performance Indicators
Check out the current performance indicators for Merck & Co Inc (MRK). In the past quarter, the stock posted a quick ratio of 1.44. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.82. Likewise, its price to free cash flow for the trailing twelve months is 18.69.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 7.56, a number that is poised to hit 2.05 in the next quarter and is forecasted to reach 8.54 in one year’s time.
Technical Analysis of Merck & Co Inc (MRK)
Looking closely at Merck & Co Inc (NYSE: MRK), its last 5-days average volume was 15.02 million, which is a jump from its year-to-date volume of 14.67 million. As of the previous 9 days, the stock’s Stochastic %D was 51.32%.
During the past 100 days, Merck & Co Inc’s (MRK) raw stochastic average was set at 74.06%, which indicates a significant increase from 22.84% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 2.33 in the past 14 days, which was higher than the 2.12 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $92.16, while its 200-day Moving Average is $85.09. However, in the short run, Merck & Co Inc’s stock first resistance to watch stands at $100.14. Second resistance stands at $102.02. The third major resistance level sits at $103.69. If the price goes on to break the first support level at $96.59, it is likely to go to the next support level at $94.92. Should the price break the second support level, the third support level stands at $93.04.
Merck & Co Inc (NYSE: MRK) Key Stats
There are currently 2,482,023K shares outstanding in the company with a market cap of 243.91 billion. Presently, the company’s annual sales total 64,168 M according to its annual income of 17,117 M. Last quarter, the company’s sales amounted to 17,276 M and its income totaled 5,785 M.
